Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$2.12 - $4.18 $358,142 - $706,148
-168,935 Reduced 93.1%
12,517 $50,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $10.04 $159,600 - $602,400
60,000 Added 49.4%
181,452 $488,000
Q2 2023

Aug 14, 2023

BUY
$7.28 - $11.82 $884,170 - $1.44 Million
121,452 New
121,452 $1.13 Billion
Q1 2023

May 15, 2023

BUY
$5.21 - $14.05 $576,825 - $1.56 Million
110,715 New
110,715 $983,000

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.